Form 4: Unicycive Director Receives RSU Grant

Director Sandeep Laumas was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc.

Summary

• Director Sandeep Laumas received two separate grants of restricted stock units (RSUs) on May 14, 2026.
• The first grant consists of 84,200 RSUs, which vest in three equal annual installments.
• The second grant consists of 42,100 RSUs, which vest in full one year after the grant date.
• Both grants are payable solely in common stock of the issuer and are subject to continued service requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and issuance of the underlying common stock.

Risks

• Vesting is contingent upon the director's continued service with the company.

Future Outlook

The RSUs will convert to common stock upon vesting, subject to the director's continued service with the company.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure leadership remains incentivized to achieve long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of multi-year vesting schedules for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• Granting annual equity awards to directors is a common mechanism to maintain competitive board compensation packages.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual issuance of common stock related to these RSUs.

Next Steps

• Vesting of 84,200 RSUs in three equal annual installments starting May 14, 2027.
• Vesting of 42,100 RSUs on May 14, 2027.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction